Contact
searchSearch
HMP Global
Login

Myelofibrosis News

News
Anemia Associated With Higher Mortality and AML Transformation Risk in Myelofibrosis
09/17/2026
Rebecca Amrick
Researchers found that the presence of anemia is likely to increase the risk of mortality and acute myeloid leukemia (AML) transformation among patients with myelofibrosis, indicating anemia as a potential prognostic marker.
Researchers found that the presence of anemia is likely to increase the risk of mortality and acute myeloid leukemia (AML) transformation among patients with myelofibrosis, indicating anemia as a potential prognostic marker.
Researchers found that the...
09/17/2026
Journal of Clinical Pathways
News
The Cost-Effectiveness of Allogeneic Stem Cell Transplantation Among Patients With Myelofibrosis
09/08/2026
Rebecca Amrick
Researchers found allogeneic stem cell transplantation (allo-SCT) to be more cost-effective than Janus kinase (JAK) inhibitor therapy among patients with high-risk myelofibrosis.
Researchers found allogeneic stem cell transplantation (allo-SCT) to be more cost-effective than Janus kinase (JAK) inhibitor therapy among patients with high-risk myelofibrosis.
Researchers found allogeneic...
09/08/2026
Journal of Clinical Pathways
News
Cytopenia Associated With Worse Survival Outcomes in Patients With Myelofibrosis
08/17/2026
Rebecca Amrick
A study found that the presence of cytopenia was associated with poor survival outcomes in patients with myelofibrosis, suggesting cytopenia as a prognostic marker to monitor during disease management.
A study found that the presence of cytopenia was associated with poor survival outcomes in patients with myelofibrosis, suggesting cytopenia as a prognostic marker to monitor during disease management.
A study found that the presence...
08/17/2026
Journal of Clinical Pathways
News
The Current Treatment Landscape for Myelofibrosis
08/10/2026
Rebecca Amrick
Researchers provided a comprehensive overview of the main treatment options for myelofibrosis (MF), including the primary Janus kinase (JAK) inhibitors, potential combination strategies, and non-pharmacologic interventions used in disease...
Researchers provided a comprehensive overview of the main treatment options for myelofibrosis (MF), including the primary Janus kinase (JAK) inhibitors, potential combination strategies, and non-pharmacologic interventions used in disease...
Researchers provided a...
08/10/2026
Journal of Clinical Pathways
News
Selinexor Plus Ruxolitinib Demonstrates Improved Efficacy in Patients With Myelofibrosis
07/22/2026
Rebecca Amrick
Selinexor plus ruxolitinib showed improved effectiveness and consistent safety than ruxolitinib alone among patients with myelofibrosis, indicating it could be a promising first-line treatment option.
Selinexor plus ruxolitinib showed improved effectiveness and consistent safety than ruxolitinib alone among patients with myelofibrosis, indicating it could be a promising first-line treatment option.
Selinexor plus ruxolitinib...
07/22/2026
Journal of Clinical Pathways
News
JAK Inhibitors Demonstrate Improved Efficacy but Worse Toxicity in Myelofibrosis
07/13/2026
Rebecca Amrick
A study found that Janus kinase (JAK) inhibitors demonstrate increased effectiveness but also higher toxicity than traditional therapies for myelofibrosis, illustrating the balance between halting disease progression and maintaining quality...
A study found that Janus kinase (JAK) inhibitors demonstrate increased effectiveness but also higher toxicity than traditional therapies for myelofibrosis, illustrating the balance between halting disease progression and maintaining quality...
A study found that Janus kinase...
07/13/2026
Journal of Clinical Pathways
News
Structural Racism Identified as Key Driver of Survival Disparities in Myelofibrosis
12/12/2025
Lisa Kuhns, PhD, MD
Structural racism, rather than biological differences or treatment patterns, appears to drive survival disparities in myelofibrosis (MF) among minority patients, according to a new multicenter analysis, according to study results published in...
Structural racism, rather than biological differences or treatment patterns, appears to drive survival disparities in myelofibrosis (MF) among minority patients, according to a new multicenter analysis, according to study results published in...
Structural racism, rather than...
12/12/2025
Journal of Clinical Pathways
News
Ruxolitinib Plus ESA or Danazol Maintains Efficacy in Patients With Myelofibrosis Who Have Anemia
10/20/2025
Grace Taylor, MS, MA
A post-hoc analysis of the phase 3b JUMP trial shows that adding erythropoiesis-stimulating agents (ESA) or danazol to ruxolitinib preserves spleen and symptom responses while supporting hemoglobin recovery in patients with myelofibrosis who...
A post-hoc analysis of the phase 3b JUMP trial shows that adding erythropoiesis-stimulating agents (ESA) or danazol to ruxolitinib preserves spleen and symptom responses while supporting hemoglobin recovery in patients with myelofibrosis who...
A post-hoc analysis of the phase...
10/20/2025
Journal of Clinical Pathways
News
Pacritinib Shows Promising Real-World Benefits for Myelofibrosis With Anemia
10/10/2025
Grace Taylor, MS, MA
A real-world data study suggests that pacritinib may improve or stabilize hemoglobin and platelet counts in patients with myelofibrosis, including those with severe anemia, reinforcing its potential utility in cytopenic populations.
A real-world data study suggests that pacritinib may improve or stabilize hemoglobin and platelet counts in patients with myelofibrosis, including those with severe anemia, reinforcing its potential utility in cytopenic populations.
A real-world data study suggests...
10/10/2025
Journal of Clinical Pathways
News
Myelofibrosis Symptom Assessment Tool Demonstrates Strong Validity and Reliability in Trials
04/15/2025
Lisa Kuhns, PhD, MD
The Myelofibrosis Symptom Assessment Form Total Symptom Score version 4.0 (MFSAF TSS v4.0) reliably captures the symptom experience of patients with myelofibrosis (MF) and effectively differentiates changes over time, supporting its role as a...
The Myelofibrosis Symptom Assessment Form Total Symptom Score version 4.0 (MFSAF TSS v4.0) reliably captures the symptom experience of patients with myelofibrosis (MF) and effectively differentiates changes over time, supporting its role as a...
The Myelofibrosis Symptom...
04/15/2025
Journal of Clinical Pathways

Special Reports

Special Report
Advancing a Standardized Economic Framework to Power Oncology Pathways: Methods and Model Development From Phase II of the Predictable Cost of Care Working Group
04/23/2026
Edward Arrowsmith, MD; Alan J. Balch, PhD, MSc; Vishnukamal Golla, MD, MPH; Andrew Hertler, MD, FACP; David Jackman, MD; Olaf Lodbrok, MS, MBA; Lalan Wilfong, MD; Gordon Kuntz; Carole Tremonti, RN, MBA
As cancer therapies expand and costs rise, oncology pathway developers need consistent, transparent methods to compare treatment options beyond drug acquisition costs. Building on Phase I’s consensus on relevant cost domains, the Phase II PCC...
As cancer therapies expand and costs rise, oncology pathway developers need consistent, transparent methods to compare treatment options beyond drug acquisition costs. Building on Phase I’s consensus on relevant cost domains, the Phase II PCC...
As cancer therapies expand and...
04/23/2026
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
08/15/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
08/15/2025
Journal of Clinical Pathways
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
08/15/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
08/15/2025
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
06/12/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
06/12/2025
Journal of Clinical Pathways
Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use